Evaluating the long-term safety and effectiveness of Growtropin®-II in children with short stature

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study assesses the long-term safety and effectiveness of Growtropin®-II treatment in children diagnosed with short stature due to growth hormone deficiency, idiopathic short stature, Turner syndrome, or being small for gestational age. The study includes children who have an official height record from at least six months prior to participation. By monitoring these children over time, the study aims to gather valuable data on the treatment's impact on growth and overall health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Children with short stature by growth hormone deficiency(GHD) or idiopathic short stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA)
* Children who has official height record at least 6 months prior

Exclusion Criteria:

* Children with Epiphyseal closure

Where it's running

• Yonsei University Health System, Severance Hospital
  Seoul, Seodaemun-gu, South Korea Recruiting

Study contacts

• Study coordinator: Sung
• Email: jhsung@donga.co.kr
• Phone: +82-2-920-8369

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating long-term safety and effectiveness of growth hormone in children with various conditions

  This study is testing how safe and effective growth hormone treatment is for children with conditions like Growth Hormone Deficiency and Turner Syndrome over the long term.

  Recruiting LG Chem · Seoul · NCT01604395

• Once-weekly lonapegsomatropin versus daily somatropin for children and adolescents with short stature due to growth-hormone-sufficient conditions

  It will test whether a once-weekly injection of lonapegsomatropin helps children and teens with Turner syndrome, SHOX mutation, small-for-gestational-age, or idiopathic short stature grow as well as or better than daily somatropin.

  Recruiting at 56 sites Phase 3 Ascendis Pharma A/S · Phoenix, Arizona and 55 other locations · NCT07221851

• Long-term Inpegsomatropin Treatment for Idiopathic Short Stature: Extension of Phase III Study

  This extension study tests whether continuing Inpegsomatropin injections helps kids with Idiopathic Short Stature who finished a prior phase 3 trial.

  Recruiting at 27 sites Xiamen Amoytop Biotech Co., Ltd. · Beijing and 26 other locations · NCT07894341

• Understanding growth hormone deficiency after a brain injury in adults

  This observational study tests whether growth hormone deficiency affects quality of life and symptoms in adults with traumatic brain injury and whether GH replacement helps after 12 weeks.

  Recruiting University of Calgary · Calgary, Alberta and 1 other locations · NCT07795736

• Inpegsomatropin vs Givopegsomatropin for short stature in girls with Turner syndrome

  A 52-week, multicenter, randomized study tests whether Inpegsomatropin injections help prepubertal girls with Turner syndrome grow taller compared with a known treatment.

  Recruiting at 49 sites Phase 3 Xiamen Amoytop Biotech Co., Ltd. · Anyang and 50 other locations · NCT07614152

• Parental plans and pregnancy outcomes in 93 women with Turner syndrome

  This project describes parental plans and pregnancy outcomes for adult women with Turner syndrome treated at Strasbourg University Hospitals between 2009 and 2019.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07344012

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.